AGENDA

I. Call to Order
II. Welcome & Introductions
III. Administrative Matters
IV. Approval of February 12, 2019 Meeting Minutes
V. PDL Compliance/Generic Percent Report Updates
VI. Drug Class Announcements
VII. Public Comment
VIII. New Drug/New Generic Reviews
   a. Antifungals, Oral- Tolsura (itraconazole) (financial review)
   b. Antineoplastics- Select Enzyme Inhibitors
      1. Copiktra (duvelisib)
      2. Daurismo (glasdegib)
      3. Vitrakvi (larotrectinib)
      4. Xospata (gilteritinib)
   c. Antiparkinson’s Agents, other- Inbrija (levodopa)
   d. Antipsychotics, Oral- Abilify Mycite (aripiprazole)
   e. Bronchodilators & COPD Agents-Yupelri (revenacin)
   f. Factor Deficiency Products- Jivi (financial review)
   g. Glucocorticoids (Inhaled)- Wixela Inhub (fluticasone/salmeterol)
      (financial review)
   h. Immune Globulins- Panzyga
   i. IBS Constipation- Motegrity (prucalopride)
   j. Miscellaneous Brand/Generic- Symjepi (epinephrine)
   k. Ophthalmic, Dry Eye Agents- Cequa (cyclosporine) (financial review)
      l. Steroids (Topical), Very High Potency- Bryhali lotion (halobetasol)
         (financial review)
IX. Division of Medicaid Update
X. Next Meeting Dates
   a. Tuesday, August 13, 2019
   b. Tuesday, October 22, 2019
XI. Adjournment